Please login to the form below

Not currently logged in
Email:
Password:

Remestemcel-L

This page shows the latest Remestemcel-L news and features for those working in and with pharma, biotech and healthcare.

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress. ... Remestemcel-L was being studied in ventilator-dependent COVID-19 patients with moderate-to-severe acute respiratory distress (ARDS).

Latest news

  • Mesoblast expands compassionate use COVID-19 programme Mesoblast expands compassionate use COVID-19 programme

    The drug, an allogeneic mesenchymal stem cell (MSC) product candidate dubbed remestemcel-L, will now be available for children between the ages of two months and 15 years old infected with ... Remestemcel-L is comprised of culture-expanded mesenchymal

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...